| Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315) |
Friederike C. Althoff |
Martin Sebastian |
| Eur J Cancer 236: 116265 |
Vollpublikation |
2026 |
|
Thorakale Onkologie
|
CRISP registry |
AIO-TRK-0315 |
| doi.org/10.1016/j.ejca.2026.116265 |
|
|
| Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy—Data From the German CRISP Registry (AIO-TRK-0315): A Brief Report |
Maximilian Rost |
Martin Sebastian |
| JTO Clin Res Rep (7)4: 100959 |
Vollpublikation |
2026 |
|
Thorakale Onkologie
|
CRISP Registry |
AIO-TRK-0315 |
| doi.org/10.1016/j.jtocrr.2026.100959 |
|
|
| Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer |
Keyl J |
Modest DP |
| Clin Cancer Res 32(5): 938-46 |
Vollpublikation |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1158/1078-0432.CCR-25-3080 |
|
|
| Prognostic and predictive value of baseline derived neutrophil-to-lymphocyte ratio (dNLR) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving 5-fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) maintenance: A post-hoc analysis of the PANAMA/AIO KRK 0212) trial |
Tobias Schaetzl |
Arndt Stahler |
| J Clin Oncol 44 (suppl 16): e15552 |
Abstract |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
PANAMA |
AIO KRK 0212 |
| doi.org/10.1200/JCO.2026.44.16_suppl.e15552 |
|
|
| Reliable segregation of survival under immunotherapy in NSCLC using simple clinical parameters |
Petros Christopoulos |
Michael Thomas |
| Oncol Res Treat 49 (suppl.1): 193-4 |
Abstract |
2026 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1159/000550849 |
|
|
| Treatment patterns, outcome and QoL of ES-SCLC patients receiving third-line therapy – Data from the German CRISP Registry (AIO-TRK-0315) |
Maximilian Rost |
Martin Sebastian |
| Oncol Res Treat 49 (suppl.1): 194 |
Abstract |
2026 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| www.doi.org/10.1159/000550849 |
|
|
| Impact of Private versus Statutory Health Insurance Status on Quality of Care and Clinical outcomes in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer – Data from the German CRISP Registry (AIO-TRK-0315) |
Fabian Acker |
Martin Sebastian |
| Oncol Res Treat 49 (suppl.1): 247-8 |
Abstract |
2026 |
|
Thorakale Onkologie
|
CRISP |
AIO-TRK-0315 |
| www.doi.org/10.1159/000550849 |
|
|
| Full cohort analysis of response and 60 day safety from the multicenter ROSE Study: Radiation during Osimertinib Treatment Safety and Efficacy Cohort |
Amanda Tufman |
Diego Kauffmann-Guerrero |
| Oncol Res Treat 49 (suppl.1): 200 |
Abstract |
2026 |
|
Thorakale Onkologie
|
ROSE |
|
| www.doi.org/10.1159/000550849 |
|
|
| Final analysis of the phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of checkpoint-inhibitor + axitinib in first line therapy (PREPARE; AIO-NZK-0115/ass; IAG-N) |
Viktor Grünwald |
Philipp Ivanyi |
| Oncol Res Treat 49 (suppl.1): 252 |
Abstract |
2026 |
|
Nierenzellkarzinom
|
PREPARE |
AIO-NZK-0115/ass |
| www.doi.org/10.1159/000550849 |
|
|
| Adjuvant Chemotherapy Alone or Combined with Atezolizumab in Patients with Stage III Deficient DNA Mismatch Repair (dMMR) Colon Cancer – Results of the Randomized ATOMIC Trial (Alliance A021502/AIO-KRK-0317) |
Dirk Arnold |
Frank Sinicrope |
| Oncol Res Treat 49 (suppl.1): 11-2 |
Abstract |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
ATOMIC |
AIO-KRK-0317 |
| www.doi.org/10.1159/000550849 |
|
|
